Endoscopic submucosal dissection for early Barrett's neoplasia: a meta-analysis
- PMID: 28993137
- DOI: 10.1016/j.gie.2017.09.038
Endoscopic submucosal dissection for early Barrett's neoplasia: a meta-analysis
Abstract
Background and aims: The role of endoscopic submucosal dissection (ESD) in Barrett's esophagus (BE) is not well established. This meta-analysis aimed to evaluate the safety and efficacy of ESD for the management of early BE neoplasia.
Methods: Three online databases were searched. The Cochran Q test and I2 were used to test for heterogeneity. Pooling was conducted using either fixed- or random-effects models depending on heterogeneity across studies. For the main outcomes, potential sources of heterogeneity were evaluated via linear regression analysis.
Results: Eleven studies (501 patients, 524 lesions) were included. Mean lesion size was 27 mm (95% confidence interval [CI], 20.9-33.1). Pooled estimate for en bloc resection was 92.9% (95% CI, 90.3%-95.2%). The pooled R0 (complete) and curative resection rates were 74.5% (95% CI, 66.3%-81.9%) and 64.9% (95% CI, 55.7%-73.6%), respectively. There was no association between R0 or curative resection rates and study setting (Asia vs West), length of BE, lesion characteristics, procedural time, or length of follow-up. The pooled estimates for perforation and bleeding were 1.5% (95% CI, .4%-3.0%) and 1.7% (95% CI, .6%-3.4%), respectively. Esophageal stricture rate was 11.6% (95% CI, .9%-29.6%). Incidence of recurrence after curative resection was .17% (95% CI, 0%-.3%) at a mean follow-up 22.9 months (95% CI, 17.5-28.3).
Conclusions: ESD for early BE neoplasia is associated with a high en bloc resection rate, acceptable safety profile, and low recurrence after curative resection. ESD should be considered as part of the armamentarium for the management of BE neoplasia.
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Comment in
-
Endoscopic submucosal dissection for early Barrett's esophagus neoplasia.Gastrointest Endosc. 2018 May;87(5):1368. doi: 10.1016/j.gie.2018.01.004. Gastrointest Endosc. 2018. PMID: 29655443 No abstract available.
-
Response.Gastrointest Endosc. 2018 May;87(5):1369. doi: 10.1016/j.gie.2018.01.022. Gastrointest Endosc. 2018. PMID: 29655444 No abstract available.
-
In the expanding arena of endoscopic management for Barrett's neoplasia, how should we fit in endoscopic submucosal dissection?Gastrointest Endosc. 2018 Jun;87(6):1394-1395. doi: 10.1016/j.gie.2018.02.004. Gastrointest Endosc. 2018. PMID: 29759155 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
